Table 3. Average Duration of Treatment (Days).
| Regimen/Treatment | Line of Treatment | |||||||
|---|---|---|---|---|---|---|---|---|
| First | Second | Third | Fourth | |||||
| Mean (SD) | Median | Mean (SD) | Median | Mean (SD) | Median | Mean (SD) | Median | |
| Rituximab-based | ||||||||
| R-mono | 28.3 (16.4) | 21 | 29.3 (54.6) | 21 | 25.6 (18.8) | 21 | 22.3 (3.1) | 21 |
| R-mono + maintenance | 483.4 (330.1) | 389.5 | 274.1 (193.8) | 199.5 | 267 (218.1) | 170.5 | 112 | 112 |
| B-R | 119 (48.9) | 140 | 91.9 (58.6) | 85 | 111.6 (57.3) | 141 | 91.7 (56.1) | 69 |
| B-R + RM | 179.7 (42) | 175 | — | — | — | — | 223 | 223 |
| Lenalidomide + rituximab | 227.5 (74.7) | 218 | 246.4 (225.2) | 156 | 76 (83.1) | 28 | — | — |
| Idelalisib + rituximab | — | — | — | — | 80 | 80 | — | — |
| Yttrium + rituximab | 7 (0) | 7z | 7.3 (0.5) | 7 | 7.3 (0.6) | 7 | — | — |
| R-CHOP | 100.9 (35.2) | 112 | 92.5 (39.9) | 115.5 | 55.8 (34.2) | 48.5 | 49 (29.7) | 49 |
| R-CHOP + RM | 1 (168) | 168 | — | — | — | — | — | — |
| R-CVP | 98.8 (38.4) | 112 | 74.3 (49.3) | 70 | 126.5 (9.2) | 126.5 | 89 (53.4) | 112 |
| R-CVP + RM | — | — | — | — | 266 | 266 | — | — |
| Non-rituximab-based | ||||||||
| Bendamustine+ obinutuzumab | 89.5 (41.1) | 109.5 | 109.2 (50.8) | 133 | 80.5 (63) | 70 | 60 (4.2) | 60 |
| CHOP | 72.7 (44.2) | 70 | 46.5 (26.3) | 28 | 70.3 (42.5) | 70 | 28 | 28 |
| CVP | 96.5 (55.1) | 115 | 56 (25.2) | 63 | 51 (32.5) | 51 | — | — |
| Ibrutinib | 355 (281.2) | 264 | 249.4 (343.8) | 81 | 177.3 (186.1) | 151 | — | — |
| Lenalidomide | 178 (178.2) | 135 | 167.1 (174.9) | 77 | 82.9 (93.1) | 55.5 | — | — |
| Idelalisib | 117.5 (73.9) | 116.5 | 147.5 (117.9) | 117 | 107.3 (65.8) | 142 | 146.5 (40.3) | 146.5 |
| All patients | 135.4 (168) | 112 | 94.8 (130.6) | 33.5 | 69.3 (102.6) | 24 | 39.3 (41.4) | 21 |
Abbreviations: B-R, bendamustine + rituximab; CHOP, cyclophosphamide + vincristine + doxorubicin (either traditional or liposomal) + prednisone; CVP, cyclophosphamide + vincristine + prednisone; R, rituximab; RM, rituximab maintenance; R-mono, rituximab monotherapy.